Daniel W Sherbenou
|Institution||University of Colorado Denver - Anschutz Medical Campus|
|2014 - 2015||Young Investigator Award - Grand Multiple Myeloma Translational Initiative, University of California, San Francisco|
|1998 - 1999||Undergraduate Honors Thesis: Two-hybrid screen for Sur-2 interactions in the C. elegans Ras pathway, University of Colorado at Boulder|
|2016 - 2016||Paul O'Hara II Seed Grant, University of Colorado Cancer Center|
|2016 - 2018||2016 Young Investigator Award, NCCN Foundation|
As an undergraduate at the University of Colorado, I started by scientific career focused on basic science research of cancer. In the laboratory of Dr. Min Han, I studied the Ras cell signaling pathway using the C. elegans model organism. In the MD/PhD program at Oregon Heath & Science University, I focused on translational leukemia research. Under the mentorship of Drs. Brian Druker and Michael Deininger, I focused on chronic myeloid leukemia. My thesis evaluated mechanisms of kinase inhibitor resistance in patients treated with imatinib (Gleevec). In oncology fellowship at University of California at San Francisco, I focused on the study of antibody-based therapeutics under the mentorship of Dr. Bin Liu. Antibody-drug conjugates (ADCs) are another rapidly growing approach to cancer treatment. With Dr. Liu, I conducting preclinical analyses of a novel ADC for multiple myeloma, with hope this this to soon lead to transition to the clinic. Now a faculty member at UC Denver in the Hematology division, I will oversee a translational research laboratory focused on novel therapy development and optimization for multiple myeloma and will care for patients with myeloma and related plasma cell disorders of Colorado and adjoining areas.
Click the "See All" links for more information and interactive visualizations!
People who are also in this person's primary department.